Last month, Bayer HealthCare announced the recipients of the 2013 Bayer Hemophilia Awards Program (BHAP). The 16 recipients, representing nine countries, received grants totaling more than $2 million in funding for undertaking innovative hemophilia research and educational initiatives. This funding covers different aspects of hemophilia, such as overcoming immunological barriers to AAV gene therapy and stem cell transplantation therapy for hemophilia.
The six US-based recipients are:
- Carl Blobel, Weill Medical College of Cornell University
- Cathy Buranahirun, Children’s Hospital Los Angeles
- Paris Margaritis, The Children’s Hospital of Philadelphia
- David Markusic, the University of Florida
- Quang Duc Tran, Emory University
- Grace Monis, University of Washington Medical Center
Since BHAP’s launch in 2002, it has awarded more than 220 grants, totaling more than $26 million, to researchers and caregivers globally.
“We’re thrilled to honor this year's award recipients, whose research will help provide greater understanding of many aspects of hemophilia in the future,” said Prasad Mathew, MD, Vice President, Global Medical Affairs Hematology, Bayer HealthCare. “BHAP is a reflection of Bayer’s ongoing commitment to research that advances scientific understanding of hemophilia, and helps improve patient care.”
Source: PRNewswire, July 9, 2013
